Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Stacey L Ackerman, Gail L Torkildsen, Eugene Mclaurin & Jason L Vittitow. (2019) Low‐dose brimonidine for relief of ocular redness: integrated analysis of four clinical trials. Clinical and Experimental Optometry 102:2, pages 131-139.
Read now
Read now
Daniel J. Oh, Judy L. Chen, Thasarat S. Vajaranant & Mark S. Dikopf. (2019) Brimonidine tartrate for the treatment of glaucoma. Expert Opinion on Pharmacotherapy 20:1, pages 115-122.
Read now
Read now
Gail L. Torkildsen, Christine M. Sanfilippo, Heleen H. DeCory & Paul J. Gomes. (2018) Evaluation of Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution, 0.025% for Treatment of Ocular Redness. Current Eye Research 43:1, pages 43-51.
Read now
Read now
Toyoaki Tsumura, Keiji Yoshikawa, Tairo Kimura, Hirotaka Suzumura, Miwako Kawashima, Mami Nanno, Kiyotaka Ishijima & Ryuji Takeda. (2014) The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients. Clinical Ophthalmology 8, pages 1681-1687.
Read now
Read now
Elad Moisseiev, Shimon Kurtz, Moshe Lazar & Gabi Shemesh. (2013) Intraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times daily. Clinical Ophthalmology 7, pages 1269-1273.
Read now
Read now
Anne J Lee & Ivan Goldberg. (2011) Emerging drugs for ocular hypertension. Expert Opinion on Emerging Drugs 16:1, pages 137-161.
Read now
Read now
Articles from other publishers (30)
Sukanya De & Chinmay Chowdhury. (2023) Substrate‐Controlled Product Divergence in Iron(III)‐Catalyzed Reactions of Propargylic Alcohols: Easy Access to Spiro‐indenyl 1,4‐Benzoxazines and 2‐(2,2‐Diarylvinyl)quinoxalines. Chemistry – A European Journal 29:13.
Crossref
Crossref
Katarzyna Asendrych-Wicik, Jakub Zarczuk, Katarzyna Walaszek, Tomasz Ciach & Magdalena Markowicz-Piasecka. (2023) Trends in development and quality assessment of pharmaceutical formulations - F2α analogues in the glaucoma treatment. European Journal of Pharmaceutical Sciences 180, pages 106315.
Crossref
Crossref
Fikret Ucar & Halil İbrahim Yener. (2022) Can bleeding in trabeculectomy be decreased? Effectiveness of brimonidine pre-treatment. European Journal of Ophthalmology 32:6, pages 3476-3481.
Crossref
Crossref
Ajay J. Khopade, Arindam Halder, Vinod Burade, Bharat Pateliya, Kaushal Jani, Vivek Patel & Shivam Upadhyay. (2022) Ophthalmic suspension of Brimonidine for sustained delivery using nano-resin/drug complex technique. Journal of Drug Delivery Science and Technology 75, pages 103594.
Crossref
Crossref
Antonio Maria Fea, Cristina Novarese, Paolo Caselgrandi & Giacomo Boscia. (2022) Glaucoma Treatment and Hydrogel: Current Insights and State of the Art. Gels 8:8, pages 510.
Crossref
Crossref
Yunli Xu & Hongyi Li. (2022) In vitro and in vivo evaluation of brimonidine loaded silica nanoparticles-laden silicone contact lenses to manage glaucoma. Journal of Biomaterials Applications 37:2, pages 333-343.
Crossref
Crossref
V. Bala Aakash, N. Ramalakshmi, S. Bhuvaneswari, E. Sankari & S. Arunkumar. (2022) Comprehensive Review on Versatile Pharmacology of Quinoxaline Derivative. Russian Journal of Bioorganic Chemistry 48:4, pages 657-677.
Crossref
Crossref
Miriam Ana González-Cela-Casamayor, José Javier López-Cano, Irene Bravo-Osuna, Vanessa Andrés-Guerrero, Marta Vicario-de-la-Torre, Manuel Guzmán-Navarro, José Manuel Benítez-del-Castillo, Rocío Herrero-Vanrell & Irene Teresa Molina-Martínez. (2022) Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment. Pharmaceutics 14:7, pages 1405.
Crossref
Crossref
Xiaotong Lou, Yuanyuan Hu, Hong Zhang, Jia Liu & Yin Zhao. (2021) Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury. Journal of Nanobiotechnology 19:1.
Crossref
Crossref
Fikret UcarServet Cetinkaya. (2021) The Results of Preoperative Use of Topical Brimonidine in Strabismus Surgery. Journal of Ocular Pharmacology and Therapeutics 37:4, pages 230-235.
Crossref
Crossref
Mari Carmen Desco, Julio Cesar Molina Martín, Jorge Mataix-Boronat, Isabel Pascual-Camps, Elena Palacios-Pozo, Marisa Barón-García, David P Piñero & Amparo Navea-Tejerina. (2021) Prophylactic effect of brimonidine to minimize the incidence of subconjunctival hemorrhage in the early postoperative period after 23G pars plana vitrectomy. Therapeutic Advances in Ophthalmology 13, pages 251584142110457.
Crossref
Crossref
M. J. Rodrigo, M. J. Cardiel, J. M. Fraile, S. Mendez-Martinez, T. Martinez-RinconM. Subias, V. PoloJ. Ruberte, T. Ramirez, E. Vispe, C. Luna, J. A. Mayoral & E. Garcia-Martin. (2020) Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model. Biomaterials Science 8:22, pages 6246-6260.
Crossref
Crossref
Fikret UcarServet Cetinkaya. (2020) The Results of Preoperative Topical Brimonidine Usage in Pterygium Surgery. Journal of Ocular Pharmacology and Therapeutics 36:4, pages 234-237.
Crossref
Crossref
V. P. Erichev & A. S. Makarova. (2019) Сompatibility of Systemic Drugs and Local Antihypertensive Therapy in Patients with Primary Open-Angle Glaucoma (Analytical Review). Ophthalmology in Russia 15:4, pages 366-373.
Crossref
Crossref
Jongwook HanWungrak ChoiWon Seok LeeHyoung Won BaeChan Yun KimGong Je Seong. (2019) The Relationship between Allergic Conjunctivitis due to Brimonidine and Systemic Allergic Disease in Glaucoma Patients. Journal of the Korean Ophthalmological Society 60:3, pages 233.
Crossref
Crossref
Teng Feng, Xiaonan Huang, Rong Ni, Wai Leung Langston Suen & Ying Chau. 2019. Nanomaterials for Drug Delivery and Therapy. Nanomaterials for Drug Delivery and Therapy
149
183
.
Eugene McLaurin, Megan E. Cavet, Paul J. Gomes & Joseph B. Ciolino. (2018) Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial. Optometry and Vision Science 95:3, pages 264-271.
Crossref
Crossref
Anu Vaajanen & Heikki Vapaatalo. (2017) A Single Drop in the Eye – Effects on the Whole Body?. The Open Ophthalmology Journal 11:1, pages 305-314.
Crossref
Crossref
Niwako Ogata, Teppei Kanda, Mizuki Kawahata, Takayasu Ichikawa, Yuki Matsumoto, Waka Morimitsu, Yukiko Nishino, Takamasa Itoi & Kayo Furumoto. (2017) Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats. Veterinary Anaesthesia and Analgesia 44:5, pages 1091-1100.
Crossref
Crossref
Alison M. Layton. (2017) Pharmacologic treatments for rosacea. Clinics in Dermatology 35:2, pages 207-212.
Crossref
Crossref
Chun Gwon Park, Young Kook Kim, Mi Jeung Kim, Min Park, Myung Hun Kim, Seung Ho Lee, Sung Yoon Choi, Won Seok Lee, You Jung Chung, Young Eun Jung, Ki Ho Park & Young Bin Choy. (2015) Mucoadhesive microparticles with a nanostructured surface for enhanced bioavailability of glaucoma drug. Journal of Controlled Release 220, pages 180-188.
Crossref
Crossref
Aimee M. Two, Wiggin Wu, Richard L. Gallo & Tissa R. Hata. (2015) Rosacea. Journal of the American Academy of Dermatology 72:5, pages 761-770.
Crossref
Crossref
Patricia Loma, Ana Guzman-Aranguez, Maria Jesus Perez de Lara & Jesus Pintor. (2015) Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency. Experimental Eye Research 134, pages 141-147.
Crossref
Crossref
Xiaoli Guo, Kazuhiko Namekata, Atsuko Kimura, Takahiko Noro, Yuriko Azuchi, Kentaro Semba, Chikako Harada, Hiroshi Yoshida, Yoshinori Mitamura & Takayuki Harada. (2015) Brimonidine suppresses loss of retinal neurons and visual function in a murine model of optic neuritis. Neuroscience Letters 592, pages 27-31.
Crossref
Crossref
J. Fowler, J. Tan, J.M. Jackson, K. Meadows, T. Jones, M. Jarratt & M. Leoni. (2015) Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema. Journal of the European Academy of Dermatology and Venereology 29:3, pages 474-481.
Crossref
Crossref
Montserrat Salleras i Redonnet & Nuria Lamas Doménech. (2014) Tratamiento del rubor facial (flushing). Piel 29:9, pages 587-591.
Crossref
Crossref
F.G. Hougeir. (2014) Érythème de la rosacée : un traitement nouveau et efficace. Annales de Dermatologie et de Vénéréologie 141, pages S169-S174.
Crossref
Crossref
David Piwnica, Carine Rosignoli, Séverine Thibaut de Ménonville, Thierry Alvarez, Marlene Schuppli Nollet, Olivier Roye, André Jomard & Jérôme Aubert. (2014) Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. Journal of Dermatological Science 75:1, pages 49-54.
Crossref
Crossref
Ethan T. Routt & Jacob O. Levitt. (2014) Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. Journal of the American Academy of Dermatology 70:2, pages e37-e38.
Crossref
Crossref
J. Fowler, M. Jarratt, A. Moore, K. Meadows, A. Pollack, M. Steinhoff, Y. Liu & M. Leoni. (2012) Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. British Journal of Dermatology 166:3, pages 633-641.
Crossref
Crossref